12.74
-0.38
(-2.90%)
As of 12:20:31 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 5 |
| Avg. Estimate | -0.93 | -0.92 | -3.53 | -4.34 |
| Low Estimate | -1.04 | -1.07 | -4.65 | -5.97 |
| High Estimate | -0.8 | -0.76 | -1.8 | -2.84 |
| Year Ago EPS | -0.55 | -0.68 | -2.89 | -3.53 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 9 | 8 |
| Avg. Estimate | -- | -- | 6.67M | 7.5M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | 60M | 60M |
| Year Ago Sales | -- | -- | -- | 6.67M |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 12.50% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.69 | -0.75 | -0.85 | -0.87 |
| EPS Actual | -0.55 | -0.68 | -0.78 | -0.86 |
| Difference | 0.14 | 0.07 | 0.07 | 0.01 |
| Surprise % | 19.71% | 9.03% | 8.45% | 1.15% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.93 | -0.92 | -3.53 | -4.34 |
| 7 Days Ago | -0.93 | -0.92 | -3.53 | -4.41 |
| 30 Days Ago | -0.87 | -0.9 | -3.5 | -4.39 |
| 60 Days Ago | -0.87 | -0.9 | -3.48 | -4.56 |
| 90 Days Ago | -0.87 | -0.9 | -3.48 | -4.56 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 1 |
| Up Last 30 Days | -- | 1 | 1 | 1 |
| Down Last 7 Days | 3 | 1 | 4 | 1 |
| Down Last 30 Days | 3 | 1 | 4 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TRML | -68.49% | -35.29% | -22.10% | -23.05% |
| S&P 500 | 6.68% | 6.74% | 9.91% | 14.34% |
Upgrades & Downgrades
| Maintains | Wedbush: Outperform to Outperform | 3/14/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/14/2025 |
| Initiated | Wedbush: Outperform | 3/6/2025 |
| Initiated | LifeSci Capital: Outperform | 2/24/2025 |
| Reiterates | Guggenheim: Buy to Buy | 12/11/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 12/11/2024 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
12.87
-8.01%
MLTX MoonLake Immunotherapeutics
37.18
-2.33%
DNTH Dianthus Therapeutics, Inc.
15.70
-7.51%
SLRN Acelyrin, Inc.
2.5400
-1.55%
VRDN Viridian Therapeutics, Inc.
11.67
-7.78%
APGE Apogee Therapeutics, Inc.
32.34
-7.57%
STTK Shattuck Labs, Inc.
0.7505
-7.69%
QTTB Q32 Bio Inc.
1.6100
+0.62%
ATXS Astria Therapeutics, Inc.
4.7400
-7.96%
TYRA Tyra Biosciences, Inc.
7.64
-7.95%